+34 679 490 537info@nanbiosis.com

News U25

Radical Dendrimers as Contrast Agents for Magnetic Resonance Imaging

José Vidal Gancedo, researcher from ICMAB-CSIC and CIBER-BBN is leading the project VIRADEN: “In vivo Studies of Radical Dendrimers as Contrast Agents for Magnetic Resonance Imaging“, one of the ICMAB Frontier Interdisciplinary Projects (FIP) 2021.

The project aims to evaluate the new contrast agents for MRI based on organic radical dendrimers developed in his group, to substitute the currently used contrast agents based on toxic metals, with the final goal of obtaining useful contrast agents in the early detection of tumors

José Vidal has explained NANBIOSIS participation in the project through Biomaterial Processing and Nanostructuring equipments of NANBIOSIS U6 counting with the expertise of José Amable Bernabé and the Ex vivo and in vivo studies with dendrimers for MRI of NANBIOSIS U25 with the expertise of Ana Paula Candiota.

ICMAB FIPs are possible thanks to the financial support from the Spanish Ministry Science and Innovation, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (CEX2019-000917-S).

Read More

Novel nano-encapsulation approach for efficient dopamine delivery in Parkinson’s treatment

UAB

Parkinson’s disease (PD) is a common neurodegenerative disorder caused by the death of dopaminergic neurons in a part of the brain (known as substantia nigra pars compacta), which leads to a deficit of dopamine (DA), one of the main neurotransmitters active in the central nervous system. Symptomatic treatment focuses on increasing the concentration of dopamine into the brain.

However, dopamine is not directly administered, because it is unable to cross the so called blood-brain barrier, which prevents some of the substances circulating in the blood to penetrate into the nervous system. Thus, DA precursor levodopa (L-DOPA) –an amino-acid which participates in the synthesis of dopamine– is used, due to its better ability to cross such barrier. Nevertheless, long-term and intermittent administration of this drug is associated with important disabling complications, such as motor disorders and involuntary muscle movements.

In a paper recently published in ACS Nano, synthetic melanin-like nanoparticles are used to overcome these limitations. This research was coordinated by Dr Daniel Ruiz-Molina, leader of the ICN2 Nanostructured Functional Materials Group, and Dr Julia Lorenzo, leader of the Protein Engineering Group at the Institute of Biotehcnology and Biomedicine (IBB) of the Universitat Autònoma de Barcelona (UAB), and was developed in collaboration with the Neurodegenerative Diseases group of Vall d’Hebron Research Institute (VHIR), led by Prof. Miquel Vila.

The main objective of this work was to obtain a “nanoplatform” –which is a biocompatible nano-structure including the substance to be delivered– able to reach the brain through a noninvasive route and generate a slow and controlled release of dopamine. A tailor-made nanoscale coordination polymer (NCP), characterized by the reversible incorporation of DA as its principal component, was tested in vitro and in vivo in rats. Intranasal administration of these nanoparticles, called DA-NCPs, showed a relevant biocompatibility, non-toxicity and a fast and efficient distribution of dopamine in the central nervous system of the animals (avoiding the blood-brain barrier).

Ex vivo and in vivo preclinical MRI acquisitions were performed at U25 of NANBIOSIS ICTS NMR: Biomedical Applications I

As reported by the researchers, the proposed method is effective in delivering dopamine to the brain and, thus, in reversing Parkinson’s symptoms. In addition, the synthetic methodology used is simple, cheap and exhibited a satisfactory yield (with a DA loading efficiency up to 60%).

These findings establish nanoscale coordination polymers as promising future candidates for efficient nasal delivery of drugs to the central nervous system, and thus for the symptomatic treatment of people affected by Parkinson’s and other neurodegenerative disorders. This type of nano-formulation and administration route may also pave the way to the development of other platforms able to deliver a wide range of drugs into the brain in a controlled manner, for the treatment of various brain diseases (such as brain tumours, Alzheimer’s, Epilepsy).

Reference article:

Javier García-Pardo, Fernando Novio, Fabiana Nador, Ivana Cavaliere, Salvio Suárez-García, Silvia Lope-Piedrafita, Ana Paula Candiota, Jordi Romero-Gimenez, Beatriz Rodríguez-Galván, Jordi Bové, Miquel Vila, Julia Lorenzo, and Daniel Ruiz-Molina, Bioinspired Theranostic Coordination Polymer Nanoparticles for Intranasal Dopamine Replacement in Parkinson’s Disease. ACS Nano 2021, 15, 5, 8592–8609, May 2021. [DOI]

Read More

Participation of NANBIOSIS U25 in the Valorisation Project MR-INITIATE

The Unit 25 of the ICTS NANBIOSIS will be enrolled, through its scientific coordinator Ana Paula Candiota, in a research valorisation project recently granted by CIBER: “Noninvasive MR-based ImagiNg of Immune sysTem action during glIoblastomA TreatmEnt (MR-INITIATE)”

Such project has the aim to increase the TRL of therapy response follow-up methods in glioblastomas, using technological approaches performed at  U25 of NANBIOSIS NMR: Biomedical Applications I

The project will be financed with € 20,000.

The CIBER-BBN transfer program

The CIBER-BBN transfer program through its call for transfer and valorization projects has been designed to promote the transfer to the industrial sector of scientific or technological results derived from the research carried out by the CIBER-BBN groups. These transfer projects will make it possible to support the commercialization of said results, since there is a company that has shown interest in them and that provides at least, the same financing than CIBER-BBN for their achievement.

The call for valorization projects is in its fourth edition, having already financed a total of fourteen projects.

Read More

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology.

According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science.

NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribute their bit to Science and highlight their essential role in nowadays research. Especially we want to recognize the work of scientists women involved in NANBIOSIS, whatever is the nature of their contribution: technical, scientific development, management, coordination, direction, etc; just to mention some examples:
Neus Ferrer and Mercedes Márquez in the Scientific Direction and Coordination of Unit 1 Protein Production Platform (PPP)
Pilar Marco and Nuria Pascual in the Management and Scientific Coordination of U2 Custom Antibody Service (CAbS) 
Miriam Royo in the Scientific Direction of U3 Synthesis of Peptides Unit
Nora Ventosa and Nathaly Segovia in the Scientific Direction and Technical Coordination of U6 Biomaterial Processing and Nanostructuring Unit
Isabel Oliveira and Teresa Galán in the Coordination of U7 Nanotecnology Unit
Rosa Villa and Gemma Gabriel in the Management and Scientific Coordination of U8 Micro – Nano Technology Unit
Gema Martínez in the Scientific Coordination of U9 Synthesis of Nanoparticles Unit
Fany Peña in the Scientific Coordination of U13 Tissue & Scaffold Characterization Unit
Mª Luisa González Martín and Margarita Hierro in the of Direction and Scientific Coordination of U16 Tissue & Scaffold Characterization Unit
Gemma Pascual and Isabel Trabado in the Coordination of the U17 Confocal Microscopy Service
Isolda Casanova in the Scientific Coordination of U18 Nanotoxicology Unit
Beatriz Moreno in the Scientific Direction of Unit 19 Clinical tests lab
Ibane Abásolo in the Scientific Coordination of Unit 20 In Vivo Experimental Platformt
Verónica Crisóstomo in the Scientific Direction of Unit 24 Medical Imaging 
Ana Paula Candiota in the Scientific Coordination of Unit 25 Biomedical Applications I 
Maria Luisa García in the Scientific Direction of U28 NanoImaging Unit from Bionand, recently incorporated to NANBIOSIS, Anna Aviñó in the Scientific Coordination of U29 Oligonucleotide Synthesis Platform (OSP) – and

Nerea Argarate in the coordination of NANBIOSIS

Thanks to all of you and your teams!

Read More

12th Workshop on Magnetic Resonance Spectroscopy and Imaging (MRI/MRS) Applied to Laboratory Animals

We are glad to inform that registration is now open for the 12th Workshop on Magnetic Resonance Spectroscopy and Imaging (MRI/MRS) Applied to Laboratory Animals, organized by the Biochemistry and Molecular Biology Department (UAB) and the Nuclear Magnetic Resonance Facility, which is also part of the NANBIOSIS ICTS U25 NMR: Biomedical Applications I. Workshop will take place February 15-18th, 2021.
This course combines a comprehensive series of lectures on the technology of Magnetic resonance spectroscopy and imaging (MRS/MRI) with hands-on laboratory sessions to provide practical demonstrations of key concepts and procedures for preclinical studies.
Whether you are considering MRI as a research tool in your lab or just would like to learn more about MRI, this workshop addresses practical aspects of experimental MRI with laboratory animals and provide valuable hands-on experience on a 7 Tesla Bruker BioSpec spectrometer.

Online registration:
(http://sermn.uab.cat/wiki/doku.php?id=formulari_curs_mri_mrs)

For more detailed information, please go to:
http://sermn.uab.cat/2021/01/12th-workshop-mrs-mri-small-animals/

Please note that a limited number of attendants is currently allowed (maximum 4). Anticipated reservation is strongly recommended.

See the workshop brochure 

Read More

Robust Conditional Independence maps of single-voxel Magnetic Resonance Spectra to elucidate associations between brain tumours and metabolites

Scientists of CIBER-BBN, Ana Paula Candiota and Margarida Juliá managing Nanbiosis ICTS U25 NMR: Biomedical Applications I have participated in the research carried out by Liverpool John Moores University and University of Valencia to elucidate associations between brain tumours and metabolites, published by the journal Plos One.

The aim of the paper is two-fold. First, to show that structure finding with the PC algorithm can be inherently unstable and requires further operational constraints in order to consistently obtain models that are faithful to the data. The authors propose a methodology to stabilise the structure finding process, minimising both false positive and false negative error rates. This is demonstrated with synthetic data. Second, to apply the proposed structure finding methodology to a data set comprising single-voxel Magnetic Resonance Spectra of normal brain and three classes of brain tumours, to elucidate the associations between brain tumour types and a range of observed metabolites that are known to be relevant for their characterisation. The data set is bootstrapped in order to maximise the robustness of feature selection for nominated target variables. Specifically, Conditional Independence maps (CI-maps) built from the data and their derived Bayesian networks have been used. A Directed Acyclic Graph (DAG) is built from CI-maps, being a major challenge the minimization of errors in the graph structure. This work presents empirical evidence on how to reduce false positive errors via the False Discovery Rate, and how to identify appropriate parameter settings to improve the False Negative Reduction. In addition, several node ordering policies are investigated that transform the graph into a DAG. The obtained results show that ordering nodes by strength of mutual information can recover a representative DAG in a reasonable time, although a more accurate graph can be recovered using a random order of samples at the expense of increasing the computation time.

Article of reference:

Robust Conditional Independence maps of single-voxel  Magnetic  Resonance  spectra  to  elucidate  associations  between  brain  tumours  and  metabolites. Raúl Vicente Casaña-Eslava, Sandra Ortega-Martorell, Paulo J. Lisboa, Ana Paula Candiota, Margarida Julià-Sapé, José David Martín-Guerrero, Ian H. Jarman 2020, PLoS ONE  https://doi.org/10.1371/journal.pone.0235057

Read More

The ATTRACT Online Conference open for registration

The on line Conference ATTRACT – Igniting the Deep Tech Revolution will take pace on 22-23 Sep 2020. The ATTRACT Online Conference website is now live! Please register before 28 August at https://attract-eu-conference.cern.b2match.io/

The ATTRACT Conference offers multiple opportunities to understand the dynamics and contribute to the emergence of a strong European deep tech ecosystem for detection and imaging technologies. The ATTRACT Project is an EC funded initiative led by a consortium of leading European research infrastructures and universities.

CIBERBBN and Nanbiosis are involved in MAGRes : Multiparametric MR approaches for non-invasive glioblastoma therapy response follow-up, one of the 170 projects using sensing and imaging technology
to enable breakthrough innovation funded by ATTRACT and headed by Ana Paula Candiota, Scientific Coordinator of NANBIOSIS U25 NMR: Biomedical Applications I

MAGRes Project:

Glioblastoma (GB) is the major aggressive primary brain tumour in adults showing disproportion between high mortality compared to low overall incidence. Survival after detection is below 18 months even after standard aggressive treatment and no cure has been reported. Novel therapies (e.g. immunotherapy) may be very expensive and it may be relevant to have in vivo, early efficiency, non-invasive imaging biomarkers (IB) to halt unsuccessful use of such therapeutic agents and allowing early evidence-based therapy-related decisions.

Researchers involved in Magret project believes that Magnetic Resonance (MR)-derived data (MRI, MRSI, i.e. imaging, spectroscopic imaging) can be translated into IB of successful GB therapy through in vivo monitoring.

MAGRes proposes a breakthrough innovative hashtag combining MRI and MRSI data acquisition. MRSI data will be used as decoding agent to translate MR-derived information into surrogate IB of successful therapeutic outcome, which definitely represents a step beyond in comparison with present follow-up therapy response strategies based in volume changes of the tumour mass.

The extremely large amount of multi-parametric data acquired for each preclinical subject (mice), longitudinal explorations with several acquisitions will allow us to benefit from powerful state-of-the-art multiparametric data analysis methods based on Deep-Learning (DL). This, together with feature selection and interpretation methods will lead to extraction of MR- based significant IB.

At present, there is no software approach allowing both fast, user-friendly post-processing of conventional MRI and MRSI, and encompassing sophisticated developments in the area of pattern recognition (PR), automated MRSI artifact removal, as well as the weighted combination of multi-parametric images.

Accordingly, MAGRes targets the development and implementation of user-friendly software with capabilities to compute 2D and 3D MR-derived parametric images and to visualise them overlaid on high resolution MR structural images. Moreover, this will be implemented in an open-source software imaging platform as a plugin, paving the way to a scalable system, which could also handle clinical patient data in the immediate future.

Read More

The Autonomous University of Barcelona, in the elite of the 300 best universities in the world

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the Autonomous University of Barcelona among the elite of the 300 best universities in the world and the first of the Spanish universities.

This indicator organizes up to 20,000 university centers worldwide,
based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings

The Autonomous University of Barcelona houses two of NANBIOSIS Units:

U1 Protein Production Platform (PPP), led by Toni Villaverde, Neus Ferrer and Paolo Saccardo, offer an “tailored” service for the design, production and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems

U25 NMR: Biomedical Applications I, led by Carles Arús and Ana Paula Candiota, with a recognized research track record in the use of NMR as a tool for biomedical applications, and more especifically to identify biomarkers of different pathologies, the main objective of this unit is the acquisition, processing and/or interpretation of Nuclear Magnetic Resonance data



Read More

Open call for contribution to the Special Issue by MDPI in IJMS about “In Vivo Biomarkers for Immunotherapy Efficacy in Brain Tumours”

Ana Paula Candiota, Scientific Coordinator of NANBIOSIS U25 NMR: Biomedical Applications I Unit (from CIBER-BBN and Autonomous University of Barcelona), is the Guest Editor of a special issue launched by MDPI in the International Journal of Molecular Sciences (IF 4.183). This special issue is about In Vivo Biomarkers for Immunotherapy Efficacy in Brain Tumours

Contributions with papers or reviews to this issue, can be fowarded to the Guest Editor (AnaPaula.Candiota@uab.cat) with a tentative title and/or abstract.

Final deadline for submission: 31/10/2020

Read More

Preclinical brain tumour therapy response assessment with MRSI approaches: Oral presentation awarded to Ana Paula Candiota


NANBIOSIS U25 scientific coordinator, Ana Paula Candiota, has recently presented a scientific work about preclinical brain tumour therapy response assessment with MRSI approaches in the 36th annual meeting of ESMRMB held in Rotterdam, Netherlands, October 3-5. Work was entitled  “Oscillatory pattern of response in MRSI-based Glioblastoma therapy follow-up: an immune system biomarker?” and was awarded an oral presentation in the scientific session of Animal Models: Brain & others

Article of refrence:
L. Villamañan, P. Calero, S. Wu, N. Arias-Ramos, M. Pumarola, S. Ortega-Martorell, M. Julià-Sapé, C. Arús, A.P. Candiota. Oscillatory pattern of response in MRSI-based Glioblastoma therapy follow-up: an immune system biomarker? European Society for Magnetic Resonance in Medicine and Biology (ESMRMB) 2019. Rotterdam, NL. Oct 2019.

Read More